- Raised funding round, Aug 2008
About
Moebius Medical is a clinical-stage biotechnology company developing novel pain-relief treatments for osteoarthritis. The company's lead product, MM-II, is a patent-protected intra-articular biolubricant injection for the treatment of mild to moderate symptomatic knee osteoarthritis. MM-II consists of proprietary liposomes whose structure facilitates cartilage surface gliding, thus reducing pain and preventing further wear and friction that can lead to joint damage. MM-II has demonstrated its ability to reduce osteoarthritic pain in a double-blind, randomized controlled trial conducted at Hadassah Medical Center, Israel. In 2016, Sun Pharma and Moebius Medical entered into an exclusive worldwide licensing deal to further develop MM-II. Moebius Medical conducts the requisite preclinical studies and assumes responsibility for product development and manufacturing through the end of phase 2 studies. Sun Pharma assumes responsibility for clinical studies, regulatory submissions, and product commercialization. In December 2020, the FDA cleared the company's Investigational New Drug application to initiate a global multi-center phase IIb clinical trial of MM-II.
Funding history · 1 round · — total
Q&A
- What is Moebius Medical's primary focus?
- Moebius Medical is a clinical-stage biotechnology company focused on developing novel pain-relief treatments for osteoarthritis.
- What is Moebius Medical's lead product?
- Moebius Medical's lead product is MM-II, a patent-protected intra-articular biolubricant injection designed to treat mild to moderate symptomatic knee osteoarthritis.
- When was Moebius Medical founded?
- Moebius Medical was founded in August 2008.
- How many employees does Moebius Medical have?
- Moebius Medical has 1-10 employees.
- Which investors participated in Moebius Medical's funding round in August 2008?
- In August 2008, Moebius Medical received funding from Yissum Research Development and Pix Vine Capital.
- What is the status of Moebius Medical's MM-II clinical trials?
- In December 2020, the FDA cleared Moebius Medical's Investigational New Drug application to begin a global multi-center phase IIb clinical trial for MM-II.
- What is the nature of Moebius Medical's partnership with Sun Pharma?
- In 2016, Moebius Medical and Sun Pharma entered an exclusive worldwide licensing deal for MM-II. Moebius Medical is responsible for preclinical studies, product development, and manufacturing through phase 2, while Sun Pharma handles clinical studies, regulatory submissions, and commercialization.
- Who is the current CEO of Moebius Medical?
- Moshe Weinstein is the CEO and a Board Member of Moebius Medical.
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | moebiusmedical.com |
|---|---|
| linkedin.com/company/10531864 |
Identifiers & details
| Founded | 2008-8 |
|---|---|
| Employees (exact) | 7 |
Radar intelligence
Patents
| EPO | 5 |
|---|
Web history (Wayback)
| Domain | moebiusmedical.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|